Comparison of Anterior Chamber Paracentesis and Conventional Mannitol Infusion in Patients With Primary Acute Angle-closure Glaucoma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

60 participants

Study Classification

OBSERVATIONAL

Study Start Date

2007-01-31

Study Completion Date

2009-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The investigators wanted to reported the results of immediate anterior chamber paracentesis (ACP), compared to Mannitol infusion, in patients with acute primary angle-closure glaucoma (PACG). In this study, the investigators first divided patients into three sub-groups according to their initial intraocular pressure (IOP) for analyzing the differences of IOP control, severity of corneal edema, waiting time for laser peripheral iridotomy (LPI), and visual outcome between ACP and Mannitol infusion.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The investigators demonstrated that ACP could be first considered in patients with initial IOP between 45 to 60 mmHg because it provided better visual outcome than Mannitol infusion through the rapid stabilization of the anterior segment, which was achieved by rapid IOP control, better corneal edema regression, shortening waiting time for LPI. However, ACP should be considered in patients with the initial IOP of 60mmHg and higher only when Mannitol was contraindicated.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Glaucoma Acute Primary Angle-closure Glaucoma

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Glaucoma anterior chamber paracentesis conventional Mannitol infusion

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Experimental Group

No interventions assigned to this group

Control Group

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* first attack of acute PACG;
* initial presenting IOP was higher than 45 mmHg;
* diagnosis confirmed by gonioscopic examination;
* patients within 48 hours of symptom onset.

Exclusion Criteria

* been incompletely followed up within 2 weeks;
* been using anti-glaucomatous medication before ACP or Mannitol infusion;
* previous intraocular surgeries on the same eye;
* contraindication for Mannitol;
* history of other vision-threatening ocular diseases.

Minimum Eligible Age

20 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Department of Ophthalmology, Wanfang Hospital

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Hui-Chun Ho

Role: PRINCIPAL_INVESTIGATOR

Taipei Medical University WanFang Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Taipei Medical University - WanFang Hospital

Taipei, , Taiwan

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Taiwan

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

99018

Identifier Type: -

Identifier Source: org_study_id